• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pharma execs assess landscape under President Trump

December 2, 2016 By Sarah Faulkner

Pharma execs assess landscape under President TrumpExecutives from U.S. drugmakers such as Regeneron Pharmaceuticals and Pfizer talked about the possible changes awaiting the industry under President-elect Donald Trump at the Forbes Healthcare Summit this week.

After he was elected, pharmaceutical stocks surged as investors concluded the threat of action on drug pricing had lessened. Trump has said he wants to repeal Obamacare, but hasn’t addressed the industry’s drug pricing problem which has largely dominated public discussion of pharmaceuticals in the past year.

Len Schleifer, CEO of Regeneron Pharmaceuticals (NSDQ:REGN), said the industry will continue to face scrutiny over its profits and pricing if it doesn’t put an end to double-digit price increases on widely-used medicines. “We as an industry have used price increases to fill gaps in innovation,” he said, according to Reuters. “You can’t say ‘I set the price based on the value of the drug’ and then have these egregious price increases.”

Allergan (NYSE:AGN) CEO Brent Saunders predicted Trump could be critical of drugmakers and become a “more vicious tweeter” against the industry than Hillary Clinton, according to Reuters. “I worry today that the pharmaceutical industry has a very false sense of security because of the Trump administration and a Republican-controlled Congress,” Saunders said.

Ian Read, CEO of Pfizer (NYSE:PFE), said he hoped to see financial risk shift from insurers to providers under a Trump presidency. “Give them the tools and the freedom and the incentive to manage that risk,” he said, according to the news outlet.

Merck‘s (NYSE:MRK) CEO Ken Frazier took issue with Trump’s proposal to allow the import of cheaper drugs from other countries, saying that current U.S. law forbids importation of drugs from other countries that charge far less than what the U.S. pays.

“I don’t think it’s going to be made possible,” said Frazier, during an interview on CNBC after appearing at the conference. “Every time we’ve tried to do that no FDA commissioner has ever been willing to certify the safety of those drugs.”

Filed Under: Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Merck, Pfizer Inc., Regeneron

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS